Browse

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout

Modern medicine is about making people better — not necessarily making them feel good.